New Research
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 13, 2026 at 8:12 AM
New Research
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
www.thelancet.com/journals/lan...
🚨 Breaking: Full 2023-24 results from the NIRSE-GAL study in Galicia, Spain, confirm effectiveness of universal nirsevimab prophylaxis in preventing RSV-related hospitalizations in infants. 📖 Published at Lancet Infectious Diseases www.thelancet.com/callback?red...
Lancet
www.thelancet.com
January 18, 2025 at 11:37 PM
🚨 Breaking: Full 2023-24 results from the NIRSE-GAL study in Galicia, Spain, confirm effectiveness of universal nirsevimab prophylaxis in preventing RSV-related hospitalizations in infants. 📖 Published at Lancet Infectious Diseases www.thelancet.com/callback?red...
- #Nirsevimab use in the 2023-24 season led to a significant reduction in RSV #bronchiolitis cases in both hospital & ambulatory settings, even with different RSV strains predominating.
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
January 14, 2026 at 1:01 AM
- #Nirsevimab use in the 2023-24 season led to a significant reduction in RSV #bronchiolitis cases in both hospital & ambulatory settings, even with different RSV strains predominating.
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
- A study in Galicia, 🇪🇸(NIRSE-GAL) found that the benefits of nirsevimab extended beyond 1st year,
The NIRSE-GAL study looking at real world impact of nirsevimab in infants in Spain.
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 13, 2026 at 2:07 PM
The NIRSE-GAL study looking at real world impact of nirsevimab in infants in Spain.
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
Of 12 492 eligible infants, 94·4% received immunization. RSV-related LRTI hospitalisations decreased by 85·9% in the 1st season and 55·3% in the 2nd.
www.thelancet.com/journals/lan... #IDSky
1) 2024 termina hoy dejándonos uno de los estudios de > impacto en prevención con #Nirsevimab contra #VRS Virus Respiratorio Sincitial, el estudio #Nirse-Gal via #lancetid y liderado por Federico Martinon-Torres y cols. Impacto fantástico. #stoprsv #pedsky #idsky #pedsidsky
doi.org/10.1016/S147...
doi.org/10.1016/S147...
Redirecting
doi.org
December 31, 2024 at 7:17 PM
1) 2024 termina hoy dejándonos uno de los estudios de > impacto en prevención con #Nirsevimab contra #VRS Virus Respiratorio Sincitial, el estudio #Nirse-Gal via #lancetid y liderado por Federico Martinon-Torres y cols. Impacto fantástico. #stoprsv #pedsky #idsky #pedsidsky
doi.org/10.1016/S147...
doi.org/10.1016/S147...